| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Kalata B7 targets the oxytocin receptor (OTR) and the vasopressin V1a receptor (AVPR1A). Oxytocin and vasopressin receptors are GPCRs involved in social behavior, reproductive functions, cardiovascular regulation, and water balance. Kalata B7 acts as a partial agonist at both receptors, meaning it activates the receptor but with lower maximal efficacy than the full endogenous agonists oxytocin and vasopressin. It also possesses membrane‑permeating capabilities, allowing it to cross cell membranes without disrupting cellular integrity.
|
|---|---|
| ln Vitro |
Kalata B7 exhibits membrane‑permeating capabilities and is a partial agonist at oxytocin and vasopressin V1a receptors. It displays selective membrane disruption properties, with studies identifying essential functional groups in the phosphatidylethanolamine binding pocket. The cyclic cystine knot (CCK) motif gives it a compact, rigid structure that is highly resistant to proteases and thermal denaturation. No specific EC₅0 values for receptor activation are reported. Kalata B7 is also a ligand for the cholecystokinin‑2 receptor (CCK2R) as reported in recent studies.
|
| ln Vivo |
No specific in vivo activity data for Kalata B7 are reported in the search results. As a membrane‑permeable cyclic peptide with partial agonist activity at oxytocin and vasopressin receptors, it has potential for evaluation in animal models of social behavior, anxiety, and cardiovascular function. The cyclotide scaffold is stable in vivo, but no specific efficacy data are provided.
|
| Enzyme Assay |
The binding of Kalata B7 to oxytocin and vasopressin V1a receptors is measured by competitive radioligand binding assays using purified recombinant receptors or cell membranes expressing the receptors. A radiolabeled ligand (e.g., [3H]‑oxytocin for OTR or [3H]‑vasopressin for V1aR) is used as a tracer. Kalata B7 is added at graded concentrations (0.1‑10,000 nM) to compete for binding, and the IC₅0 or Ki is calculated from dose‑response curves. Purity is typically ≥95% (HPLC).
|
| Cell Assay |
For cellular assays, cells expressing oxytocin or vasopressin V1a receptors (e.g., HEK293‑OTR or HEK293‑V1aR cells) are seeded in 96‑well plates. Kalata B7 is added at graded concentrations (0.1‑10,000 nM) for 15‑30 min. Receptor activation is assessed by measuring intracellular calcium levels using a fluorescent indicator (e.g., Fluo‑4 AM) or by measuring inositol phosphate (IP) accumulation using an ELISA‑based IP assay. The partial agonist activity is determined by comparing the maximum response to that induced by the full agonists oxytocin or vasopressin. The EC₅0 is calculated from dose‑response curves.
|
| Animal Protocol |
No animal experiments for Kalata B7 are described in the search results. For in vivo evaluation of oxytocin receptor activation, 6‑8‑week‑old female C57BL/6 mice would be used in behavioral assays such as the open field test, social interaction test, or forced swim test. Kalata B7 would be administered intracerebroventricularly (ICV) at doses of 0.1‑10 ug per mouse, and behavioral responses would be recorded. Due to its membrane‑permeating properties, it may also be effective after peripheral administration. No such data are provided.
|
| ADME/Pharmacokinetics |
Kalata B7 (C12₈H1₉₆N3₆O40S₆, MW = 3071.53, purity ≥95%, CAS 339532‑29‑5) is a lyophilized solid powder. For storage, the powder should be kept at -20 degC for up to 3 years, sealed and protected from light. For in vitro use, stock solutions in DMSO (1‑10 mM) can be prepared and stored at -80 degC for up to 6 months or at -20 degC for 1 month. The peptide is soluble in DMSO and other organic solvents. For in vivo use, it can be formulated in 10% DMSO / 40% PEG300 / 5% Tween‑80 / 45% saline.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for Kalata B7 are reported. As a research‑grade cyclic peptide, it is not intended for human or veterinary use. Standard laboratory safety precautions for handling peptides should be followed, including the use of gloves, lab coat, and safety goggles. No LD₅0 or formal toxicology studies are available.
|
| References |
|
| Additional Infomation |
Kalata B7 is a cyclotide isolated from the plant Oldenlandia affinis DC (Rubiaceae). Cyclotides are a family of plant‑derived cyclic peptides characterized by a head‑to‑tail cyclized backbone and a knotted arrangement of three disulfide bonds, known as a cyclic cystine knot (CCK). This unique structure confers exceptional stability, making cyclotides resistant to proteolysis, extreme temperatures, and chemical denaturation. Kalata B7 is one of several cyclotides from this plant, originally named for the traditional medicinal use of Oldenlandia affinis to accelerate childbirth (kalata means “to speed up” in the local language). The compound is for research use only and has not received regulatory approval.
|
| Molecular Formula |
C128H196N36O40S6
|
|---|---|
| Molecular Weight |
3071.53
|
| CAS # |
339532-29-5
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3256 mL | 1.6279 mL | 3.2557 mL | |
| 5 mM | 0.0651 mL | 0.3256 mL | 0.6511 mL | |
| 10 mM | 0.0326 mL | 0.1628 mL | 0.3256 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
